Cancer Research UK has shortlisted ten multidisciplinary, international teams for what amounts to the second leg of competition for Grand Challenge awards.
FDA approved abiraterone acetate (Zytiga) tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). The drug is sponsored by Janssen Biotech Inc.
Foundation Medicine Inc. and the European Organisation for Research and Treatment of Cancer announced a collaboration in which Foundation Medicine's comprehensive genomic profiling tests will be used to inform patient eligibility for oncology clinical trials through the EORTC's Screening Patients for Efficient Clinical Trial Access program, which is a pan-European network built by the EORTC with key institutions collaborating to provide efficient access for patients to molecularly driven clinical trials.
ANGLE plc has signed an agreement with Abbott in which Abbott will supply ANGLE with its proprietary PathVysion HER-2 DNA FISH Probe kits for ANGLE's ANG-002 FDA study for FISH (fluorescence in situ hybridization) analysis of circulating tumor cells in the form of a research grant.
Genentech announced results from the positive phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
Bristol-Myers Squibb Company said the ongoing phase III CheckMate-227 study met its co-primary endpoint of progression-free survival with the Opdivo (nivolumab) plus Yervoy (ipilimumab) combination versus chemotherapy in first-line advanced non-small cell lung cancer patients whose tumors have high (≥10 mutations/megabase, mut/mb) tumor mutation burden, regardless of PD-L1 expression.
Tyme Technologies Inc. announced efficacy and safety data from an ongoing phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent prostate cancer.
Wadih Arap was named director of Rutgers Cancer Institute of New Jersey at University Hospital.
Madhav Dhodapkar, an expert in cancer immunology and translational immunotherapy, will join Winship Cancer Institute of Emory University on March 1 as the director of the new Winship Center for Cancer Immunology.
Paul Oberstein will join NYU Langone Health and its Perlmutter Cancer Center March 1 as director of gastrointestinal medical oncology and assistant director of its recently established Pancreatic Cancer Center.
